Business Wire

Bayer to Unveil New Data From Its Phase III OASIS 3 Long-Term Study of Elinzanetant in the ...

Christian Seitz Thursday, September 12, 06:15 PM to 7:15 PM CT, Location: Riverside East, Riverside West/South – Exhibit Hall Level- East Tower Poster #122: “Do sleep disturbances have an impact on ...
Nasdaq

Bayer’s Lynkuet® (elinzanetant), the First and Only Neurokinin 1 and Neurokinin 3 ...

This approval is supported by data from the Phase III OASIS clinical trial program evaluating Lynkuet for the treatment of moderate to severe hot flashes due to menopause1 In OASIS 1 and OASIS 2, ...
Business Wire

Bayer to Investigate Finerenone in Phase III Study in Adults With Chronic Kidney Disease ...

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today the initiation of FINE-ONE, a global, multicenter, randomized, placebo-controlled, double-blind, parallel-group Phase III study to evaluate the ...
GEN

Bayer, Kumquat Target KRAS Variant in Up-to-$1.3B+ Cancer Collaboration

Bayer will partner with Kumquat Biosciences to develop Kumquat’s KRAS G12D inhibitor through a collaboration that could generate up to $1.3 billion-plus for the San Diego biotech, while bolstering ...
Reuters

Bayer adds cancer drug candidate to portfolio with $1.3-billion Kumquat deal

BERLIN, Aug 12 (Reuters) - German pharmaceutical group Bayer (BAYGn.DE), opens new tab announced on Tuesday a deal worth up to $1.3 billion with Kumquat Biosciences to develop the U.S.-based oncology ...